타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | sacituzumab govitecan-hziy (Trodelvy, IMMU-132, sacituzumab-govitecan-hziy) Gilead / Immunomedics·TROP2 242 trials | |||
|---|---|---|---|---|
Overview Program | Herceptin (trastuzumab) | Enhertu (fam-trastuzumab deruxtecan-nxki) | Kadcyla (ado-trastuzumab emtansine) | Trodelvy (sacituzumab govitecan-hziy) |
Overview Company | Roche / Genentech | Daiichi Sankyo / AstraZeneca | Roche / Genentech | Gilead / Immunomedics |
Overview Modality | ANTIBODY | ADC | ADC | ADC |
Overview Target | HER2 | HER2 | HER2 | TROP2 |
Overview Indication | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow breast cancer, HER2-positive gastric cancer, HER2-mutant NSCLC and HER2-positive solid tumors: consult the current US label | HER2+ breast cancer | TNBC: regimen-specific first-line and previously treated indications; HR-positive/HER2-negative breast cancer after specified prior therapies. Consult current US label. |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT | High DAR (~8), bystander effect, HER2-low activity | Stable linker, DAR ~3.5 | Very high DAR plus a deliberately unstable linker — extracellular SN-38 release gives bystander killing in TROP2-heterogeneous tumors. |
Positioning Known limitation | resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes | HER2 antigen loss/downregulation, payload efflux, and dose-limiting ILD/pneumonitis leading to discontinuation. | HER2 downregulation, lysosomal trapping, and efflux; superseded in 2L HER2+ mBC by trastuzumab deruxtecan (DESTINY-Breast03). | TROP2 downregulation, TOP1 mutation, and ABC-transporter payload efflux. |
Positioning Development positioning | — | Indication- and regimen-specific; includes 1L + pertuzumab in HER2-positive metastatic breast cancer | 2L | Regimen-specific; includes 1L TNBC indications from June 2026 |
Technology Payload | — | DXd (topo-I inhibitor) | DM1 (maytansine derivative) | SN-38 (topoisomerase I inhibitor) |
Technology Linker | — | Cleavable tetrapeptide | Non-cleavable stable thioether MCC | Hydrolyzable CL2A, DAR ~7.6 |
Technology DAR | — | — | — | DAR 7.6 |
MoA Mechanism | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. | Ado-trastuzumab emtansine (T-DM1) binds HER2 on tumor cells, is internalized, and MMAE is released after lysosomal degradation of the antibody in the non-cleavable SMCC linker system. MMAE disrupts microtubules, causing G2/M arrest and apoptosis. | Anti-TROP2 antibody binds and internalizes; the hydrolyzable linker releases SN-38 both intracellularly and in the tumor microenvironment, inhibiting topoisomerase I and causing lethal DNA double-strand breaks. |
MoA Biomarker | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). | HER2 overexpression/amplification (IHC 3+ or ISH+ per label). | TROP2 is broadly expressed in epithelial tumors; no companion diagnostic is required in the label. |
Toxicology Species | Rat | Cynomolgus monkey, NHP, Rat, Hamster | Cynomolgus monkey, Rat | Cynomolgus monkey, Hamster |
Toxicology Animal (cat.) | — | NHP | NHP | — |
Toxicology Major finding | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | ILD-like lung findings at high exposure | Thrombocytopenia, hepatotoxicity | Boxed warning for severe neutropenia and severe diarrhea. Nausea, alopecia, fatigue, and rare hypersensitivity are common. |
Toxicology CRS | N/A | Minimal | Minimal | N/A |
Toxicology NOAEL | — | 10 mg/kg | — | — |
Clinical Safety signal | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | ILD-like lung findings at high exposure | Thrombocytopenia, hepatotoxicity | Boxed warning for severe neutropenia and severe diarrhea. Nausea, alopecia, fatigue, and rare hypersensitivity are common. |
Clinical Selected reported efficacy | — | ORR 87% | — | ORR 50% |
Clinical Reported ORR | — | 87% vs 81% (THP) | — | 50% vs 47% (chemotherapy) |
Clinical Reported PFS | — | 40.7 months vs 26.9 months (THP) | — | 9.7 months vs 6.9 months (chemotherapy) |
Clinical Reported OS | — | Immature at the reported PFS analysis | — | Immature in FDA approval analysis |
Clinical Result source | — | FDA label 2026, Table 28 — DESTINY-Breast09 (NCT04784715) | — | FDA approval report 2026-06-24 — ASCENT-03 (NCT05382299) |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | NCT04784715 | — | NCT05382299 |
Preclinical Animal (cat.) | Mouse, In vitro | Human, Mouse, In vitro | In vitro | Mouse |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | sacituzumab govitecan-hziy (Trodelvy, IMMU-132, sacituzumab-govitecan-hziy) Gilead / Immunomedics·TROP2 242 trials | |||
|---|---|---|---|---|
Overview Program | Herceptin (trastuzumab) | Enhertu (fam-trastuzumab deruxtecan-nxki) | Kadcyla (ado-trastuzumab emtansine) | Trodelvy (sacituzumab govitecan-hziy) |
Overview Company | Roche / Genentech | Daiichi Sankyo / AstraZeneca | Roche / Genentech | Gilead / Immunomedics |
Overview Modality | ANTIBODY | ADC | ADC | ADC |
Overview Target | HER2 | HER2 | HER2 | TROP2 |
Overview Indication | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow breast cancer, HER2-positive gastric cancer, HER2-mutant NSCLC and HER2-positive solid tumors: consult the current US label | HER2+ breast cancer | TNBC: regimen-specific first-line and previously treated indications; HR-positive/HER2-negative breast cancer after specified prior therapies. Consult current US label. |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT | High DAR (~8), bystander effect, HER2-low activity | Stable linker, DAR ~3.5 | Very high DAR plus a deliberately unstable linker — extracellular SN-38 release gives bystander killing in TROP2-heterogeneous tumors. |
Positioning Known limitation | resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes | HER2 antigen loss/downregulation, payload efflux, and dose-limiting ILD/pneumonitis leading to discontinuation. | HER2 downregulation, lysosomal trapping, and efflux; superseded in 2L HER2+ mBC by trastuzumab deruxtecan (DESTINY-Breast03). | TROP2 downregulation, TOP1 mutation, and ABC-transporter payload efflux. |
Positioning Development positioning | — | Indication- and regimen-specific; includes 1L + pertuzumab in HER2-positive metastatic breast cancer | 2L | Regimen-specific; includes 1L TNBC indications from June 2026 |
Technology Payload | — | DXd (topo-I inhibitor) | DM1 (maytansine derivative) | SN-38 (topoisomerase I inhibitor) |
Technology Linker | — | Cleavable tetrapeptide | Non-cleavable stable thioether MCC | Hydrolyzable CL2A, DAR ~7.6 |
Technology DAR | — | — | — | DAR 7.6 |
MoA Mechanism | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. | Ado-trastuzumab emtansine (T-DM1) binds HER2 on tumor cells, is internalized, and MMAE is released after lysosomal degradation of the antibody in the non-cleavable SMCC linker system. MMAE disrupts microtubules, causing G2/M arrest and apoptosis. | Anti-TROP2 antibody binds and internalizes; the hydrolyzable linker releases SN-38 both intracellularly and in the tumor microenvironment, inhibiting topoisomerase I and causing lethal DNA double-strand breaks. |
MoA Biomarker | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). | HER2 overexpression/amplification (IHC 3+ or ISH+ per label). | TROP2 is broadly expressed in epithelial tumors; no companion diagnostic is required in the label. |
Toxicology Species | Rat | Cynomolgus monkey, NHP, Rat, Hamster | Cynomolgus monkey, Rat | Cynomolgus monkey, Hamster |
Toxicology Animal (cat.) | — | NHP | NHP | — |
Toxicology Major finding | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | ILD-like lung findings at high exposure | Thrombocytopenia, hepatotoxicity | Boxed warning for severe neutropenia and severe diarrhea. Nausea, alopecia, fatigue, and rare hypersensitivity are common. |
Toxicology CRS | N/A | Minimal | Minimal | N/A |
Toxicology NOAEL | — | 10 mg/kg | — | — |
Clinical Safety signal | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | ILD-like lung findings at high exposure | Thrombocytopenia, hepatotoxicity | Boxed warning for severe neutropenia and severe diarrhea. Nausea, alopecia, fatigue, and rare hypersensitivity are common. |
Clinical Selected reported efficacy | — | ORR 87% | — | ORR 50% |
Clinical Reported ORR | — | 87% vs 81% (THP) | — | 50% vs 47% (chemotherapy) |
Clinical Reported PFS | — | 40.7 months vs 26.9 months (THP) | — | 9.7 months vs 6.9 months (chemotherapy) |
Clinical Reported OS | — | Immature at the reported PFS analysis | — | Immature in FDA approval analysis |
Clinical Result source | — | FDA label 2026, Table 28 — DESTINY-Breast09 (NCT04784715) | — | FDA approval report 2026-06-24 — ASCENT-03 (NCT05382299) |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | NCT04784715 | — | NCT05382299 |
Preclinical Animal (cat.) | Mouse, In vitro | Human, Mouse, In vitro | In vitro | Mouse |
추천 비교
추천 비교